Q-omics provides the consensus-scored STEAP1 profile across patient tissues and cancer cell-line models. STEAP1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, STEAP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, STEAP1 RNA expression shows 16,297 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, HNSC, and THYM as cancer lineages where STEAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STEAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STEAP1 survival associations across molecular data types. STEAP1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STEAP1 RNA expression–survival associations across cancer types. High STEAP1 expression shows unfavorable associations in LUAD, ACC and LGG, but favorable associations in KIRC, UVM and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for STEAP1 RNA expression.
This table summarizes STEAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STEAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STEAP1 shows higher tumor expression in HNSC, LUAD, STAD, LUSC, READ and KIRC. The HNSC box plot shows higher STEAP1 RNA expression in tumor versus normal tissue (log2 FC = +1.343, t-test p < 0.001).
This table shows molecular features associated with STEAP1 in patient tissues and cancer cell lines. In patient samples, STEAP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STEAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
